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ABSTRACT
Introduction: A striking epidemiological feature of esophageal adenocarcinoma 
(EAC) is its strong, unexplained male predominance but few studies have evaluated 
the prevalence of sex hormone receptor expression in EAC. 
Results: A low proportion of EAC tumors stained positive for ERα (4%) and AR 
(3%) while approximately one third stained positive for ERβ (31%). After a mean 
follow-up of 3 years (max 9 years), no significant associations were seen for ERα, 
ERβ or AR expression and EAC recurrence or survival. A non-significant reduction 
in mortality was observed for positive ERβ tumor expression, when restricting to 
patients with gastro-esophageal junctional (GEJ) cancer (HR 0.58, 95% CI 0.33, 
1.03, p = 0.06). 
Materials and Methods: We identified all EAC patients who underwent neo-
adjuvant chemotherapy prior to surgical resection between 2004–2012 in the Northern 
Ireland Cancer Centre. Immunohistochemical expression of ERα, ERβ and AR was 
scored on triplicate cores to generate H-scores. Cox proportional hazards regression 
was used to evaluate the association between sex hormone receptor expression and 
overall, cancer-specific and recurrence-free survival. 
Conclusion: We found little evidence of ERα or AR expression in EAC. A moderate 
proportion expressed ERβ and there was suggestive evidence that its expression was 
associated with improved survival in GEJ cancer patients. 
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INTRODUCTION
The incidence of esophageal adenocarcinoma 
(EAC) is rising and prognosis remains poor [1, 2]. Despite 
advances in oncological and surgical management the 
five-year survival rate for EAC is only 15%, and even 
in early localized disease treated with peri-operative 
chemotherapy, survival is less than 40% [3, 4]. Attempts 
to improve prognosis have focused on the surveillance 
of Barrett’s esophagus, the precursor to EAC, but only 
a small proportion of patients have a previous Barrett’s 
diagnosis [5, 6]. The most striking epidemiological feature 
of EAC is its strong unexplained male predominance 
[7–9], with male-to-female incidence ratios of up to 6:1 
observed [10, 11]. This has led to the suggestion of sex 
hormone involvement in EAC development, possibly via 
estrogenic protection, a detrimental effect of androgens, 
or both [12, 13].
           Research Paper
Oncotarget35301www.oncotarget.com
Recent epidemiological evidence demonstrates 
associations between circulating sex steroid hormones and 
EAC risk [14]. Moreover, prognosis after surgical resection 
of EAC has been shown to be better in females compared 
to males [15, 16]. Mounting preclinical evidence supports 
the hypothesis that sex hormones may be important 
in EAC pathogenesis [7]. Estrogens decrease tumor 
growth and increase apoptosis in EAC cell lines [17], 
while estrogen replacement has been shown to suppress 
esophageal damage of reflux esophagitis in animal models 
[18] and reduce esophageal tumor growth [19]. Androgen 
receptor (AR) is a key mediator of inflammatory signals 
in esophageal cancer progression and its expression has 
been shown to promote cell migration, invasion and 
proliferation in esophageal cancer in vivo [13, 20].
Although the exact mechanisms underlying sex 
hormone involvement in esophageal carcinogenesis remain 
unclear, it is potentially mediated through sex hormone 
receptors including estrogen receptors (ER) and AR [21]. 
ERα is predominantly expressed in female sex organs 
including the breast, uterus and ovaries while ERβ is widely 
expressed in many other tissues, including the esophagus, 
in both males and females [13, 22]. Other sex hormone 
receptors include the progesterone receptor, activated by 
the steroid hormone progesterone, and related receptors 
include G protein-coupled estrogen receptors (GPER), 
such as G protein-coupled estrogen receptor 1 or GPR30, 
which exert their physiological effects through ERα and β 
via pregenomic pathways [23]. Clinical studies have shown 
complex patterns of ER expression in EAC specifically 
but few studies have been conducted and to date they have 
been small in size (e.g. 11–28 cases) [24–28]. Similarly, 
few studies have investigated AR expression in EAC tissue 
[27, 29, 30]. The association between sex hormone receptor 
expression and EAC prognosis has also received little 
attention; one study reported an inverse association between 
ERβ expression and cancer-specific survival [24] while 
another observed no association between AR expression and 
overall survival [30]. 
Considering that ER and AR signalling can be 
modulated through existing therapeutic selective targeting (in 
addition to emerging novel techniques such as selective ERβ 
agonists), further understanding of the role of sex hormone 
receptors in EAC is important considering that molecular-
targeted intervention may offer opportunities for primary 
and secondary prevention. In a UK cohort study, we aimed 
to determine prevalence of ERα, ERβ and AR expression in 
EAC tissue, and to investigate the influence of sex hormone 
receptor expression on EAC recurrence and survival.
RESULTS
Patient cohort
During the study period, a total of 158 formalin-
fixed paraffin embedded (FFPE) EAC resection specimens 
were collected from the Northern Ireland Cancer Centre. 
Clinical information was available for 154 of these 
patients. Four patients were excluded on the basis of 
complete pathological response (ypT0) following neo-
adjuvant chemotherapy, in addition to one patient who 
had metastases present at the time of surgery. Patients 
were additionally excluded if they lacked sufficient tumor 
within cores for immunohistochemical scoring leaving a 
total of 139, 138 and 138 in analysis of ERα, ERβ and 
AR, respectively, see Figure 1. The majority of included 
patients were male (78%) and average age at EAC 
diagnosis was 63 years. Most patients had tumors located 
in the gastro-esophageal junctional (GEJ) (83%). 
Patient characteristics by sex hormone receptor 
status are listed in Table 1. Although the prevalence 
of positive sex hormone receptor expression did not 
significantly differ by sex, the majority of ERα and ERβ 
positive expression was in male EAC patients (83.3% and 
79.1%, respectively), while positive expression of AR was 
only observed in males, see Figure 2.
Although only a minority of tumors expressed 
ERα, patients whose tumors expressed ERα were more 
likely to have three or more disease positive nodes (i.e. 
at least ypN2 disease) compared to patients with negative 
expression. Demographic and lifestyle factors did not 
differ significantly according to sex hormone receptor 
status and similarly, there were no significant differences 
in tumor characteristics by ERα, ERβ or AR expression 
(Table 1). Average duration of follow-up was 3 years and 
ranged from 4 months to 9 years.
Sex hormone receptor expression 
Figure 3A–3C shows the immunohistochemical 
cellular staining according to positive and negative ERα 
expression. A low proportion of positive (nuclear) ERα 
staining was observed in 6 out of 139 patients (4.3%), Figure 
3A. A moderate proportion of EAC tumors were found to 
positively express ERβ, which was predominantly nuclear 
in nature (43 out of 138 patients (31%)) (Figure 3B). A small 
proportion of EAC tumors were positive for AR nuclear 
expression (4 out of 138 (2.9%)) (Figure 3C). Overall, the 
observed staining was largely homogenous in nature.
ERα expression and EAC progression
During follow-up, 86 cancer recurrences, 78 EAC-
specific deaths and 83 deaths from any cause occurred. 
Results for ERα expression and associated risk of EAC 
clinical outcomes are listed in Table 2. Unadjusted 
analysis did not demonstrate any significant associations 
between ERα expression and risk of cancer recurrence, 
cancer-specific or overall survival and results were similar 
following adjustment for potential confounders (HR 1.32, 
95% CI 0.41, 4.24), (HR 1.14, 95% CI 0.29, 4.50) and 
(HR 1.36, 95% CI 0.44, 4.23), respectively.
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ERβ expression and EAC progression
In analysis of ERβ expression, a total of 87 
recurrences, 79 cancer-specific deaths and 84 deaths 
from any cause were observed during follow-up. In 
adjusted analyses, improvements in overall survival 
(HR 0.71, 95% CI 0.41, 1.21), cancer-specific survival 
(HR 0.73, 95% CI 0.42, 1.28) and recurrence-free 
survival (HR 0.89, 95% CI 0.53, 1.48) were observed 
for patients whose tumors expressed ERβ compared to 
those whose tumors were negative for ERβ, however 
results were not statistically significant.
AR expression and EAC progression
In analysis of AR expression, there were 86 cancer 
recurrences, 78 deaths from EAC and 83 deaths from 
any cause identified during follow-up. No significant 
associations were observed for AR positive expression and 
risk of EAC outcomes, Table 2. Although HRs were raised 
in unadjusted analysis, they attenuated following adjustment 
for potential confounders and remained non-significant; 
overall survival (adjusted HR 1.50, 95% CI 0.49, 4.62), 
cancer-specific survival (HR 1.48, 95% CI 0.48, 4.55) and 
recurrence-free survival (HR 1.50, 95% CI 0.49, 4.57).
Sensitivity analysis 
Table 3 presents the results of sensitivity analyses 
restricting the cohort to patients diagnosed with tumors 
located in the GEJ. Overall, results were similar to the 
main analysis with no significant associations observed for 
ERα or AR expression and risk of any outcome following 
adjustment for potential confounders. ERβ expression was 
associated with a reduced risk of death from any cause 
(HR 0.58, 95% CI 0.33, 1.03, p = 0.06) and reduced 
cancer-specific mortality (HR 0.59, 95% CI 0.32, 1.07, 
p = 0.08), although results failed to reach statistical 
significance. A less marked (non-significant) association 
was seen for ERβ expression and recurrence-free survival 
(HR 0.75, 95% CI 0.43, 1.29).
DISCUSSION
In a population-representative study of EAC patients 
who underwent neoadjuvant chemotherapy prior to 
surgical resection, we found little evidence of ERα or AR 
expression in EAC while expression of ERβ was identified 
in approximately one third of tumors. No significant 
associations were observed between ERα, ERβ or AR 
expression and overall, cancer-specific or recurrence-free 
Figure 1: Study selection process for analysis of ERα, ERβ and AR expression in esophageal adenocarcinoma patients. 
Abbreviations: ER = estrogen receptor, AR = androgen receptor, α = alpha, β = beta.
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Table 1: Characteristics of EAC patients by sex hormone receptor expression
ERα receptor status ERβ receptor status AR status
Negative
(n = 133)
Positive
(n = 6)
P Negative
(n = 95)
Positive
(n = 43)
P Negative
(n = 134)
Positive
(n = 4)
P
Sex
Male 104 (78.2) 5 (83.3) 0.76 74 (77.9) 34 (79.1) 0.88 104 (77.6) 4 (100) 0.28
Female 29 (21.8) 1 (16.7) 21 (22.1) 9 (20.9) 30 (22.4) 0
Age at diagnosis (years)
<50 13 (9.8) 1 (16.7) 0.71 10 (10.5) 4 (9.3) 0.94 14 (10.4) 0 0.60
50–59 24 (18.0) 2 (33.3) 18 (18.9) 10 (23.3) 26 (19.4) 0
60–70 63 (47.4) 2 (33.3) 45 (47.4) 19 (44.2) 62 (46.3) 3 (75)
≥70 33 (24.8) 1 (16.7) 22 (23.2) 10 (23.3) 32 (23.9) 1 (25)
Smoking status
Non-smoker 34 (29.1) 1 (16.7) 0.38 24 (28.2) 12 (32.4) 0.52 34 (25.4) 1 (25) 0.38
Ex-smoker 29 (24.8) 3 (50) 20 (23.5) 12 (32.4) 32 (23.9) 0
Current smoker 54 (46.1) 2 (33.3) 41 (48.2) 13 (35.1) 52 (38.8) 3 (75)
Unknown 16 0 10 6 16 0
Alcohol 
Non-drinker 42 (37.5) 2 (33.3) 0.84 28 (34.6) 16 (44.4) 0.58 42 (37.2) 1 (25) 0.62
Drinker 70 (62.5) 4 (66.7) 53 (65.4) 20 (55.6) 71 (62.8) 3 (75)
Unknown 21 0 14 7 21 0
Primary tumor site
Lower third 22 (16.5) 0 0.28 15 (15.8) 7 (16.3) 0.94 22 (16.4) 0 0.38
Gastro-
esophageal 
junction
111 (83.5)  6 (100) 80 (84.2) 36 (83.7) 112 (83.6) 4 (100)
Siewert classificationa
Siewert I 65 (58.6) 4 (66.7) 0.69 48 (60) 21 (58.3) 0.87 66 (58.9) 2 (50) 0.72
Siewert II/III 46 (41.4) 2 (33.3) 32 (40) 15 (41.7) 46 (41.1) 2 (50)
PET response
No 40 (40.8) 4 (66.7) 0.21 28 (39.4) 16 (48.5) 0.38 44 (43.6) 0 0.22
Yes 58 (59.2) 2 (33.3) 43 (60.6) 17 (51.5) 57 (56.4) 2 (100)
Unknown 35 0 24 10 33 2
Lymphatic vascular invasion
No 40 (30.3) 3 (50) 0.31 29 (30.8) 13 (30.2) 0.94 42 (31.6) 0 0.39
Yes 92 (69.7) 3 (50) 65 (69.2) 30 (69.8) 91 (68.4) 4 (100)
Unknown 1 0 1 0 1 0
Grade
Well 4 (3) 0 0.87 4 (4.2) 0 0.32 4 (3) 0 0.84
Moderate 51 (38.3) 2 (33.3) 37 (38.9) 15 (34.9) 50 (37.3) 2 (50)
Poor 78 (58.7) 4 (66.7) 54 (56.8) 28 (65.1) 80 (59.7) 2 (50)
Circumferential resection margin status
Negative 72 (54.5) 3 (50) 0.83 54 (57.5) 19 (44.2) 0.15 73 (54.9) 1 (25) 0.24
Positive 60 (45.5) 3 (50) 40 (42.5) 24 (55.8) 60 (45.1) 3 (75)
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survival. This is the first study to investigate sex hormone 
receptor expression in EAC patients by tumor location and 
there was a suggestion that ERβ expression was associated 
with a reduction in the risk of all-cause and cancer-specific 
death in patients with GEJ cancer, albeit findings did not 
reach statistical significance. 
Previous research into sex hormone receptor 
expression in EAC has been sparse and contradictory 
Unknown 1 0 1 0 1 0
Surgical T stage
1 11 (8.3) 1 (16.7) 0.87 8 (8.4) 4 (9.3) 0.95 11 (8.2) 1 (25) 0.53
2 26 (19.6) 1 (16.7) 16 (16.8) 8 (18.6) 26 (19.4) 0
3 91 (68.4) 4 (66.7) 67 (70.5) 30 (69.8) 92 (68.7) 3 (75)
4 5 (3.8) 0 4 (4.2) 1 (2.3) 5 (3.7) 0
Surgical N stage 
0 45 (33.8) 2 (33.3) 0.04 31 (32.6) 15 (34.8) 0.23 45 (33.6) 1 (25) 0.51
1 29 (21.8) 0 23 (24.2) 6 (14) 28 (20.9) 1 (25)
2 32 (24.1) 0 23 (24.2) 8 (18.6) 30 (22.4) 2 (50)
3 27 (20.3) 4 (66.7) 18 (19) 14 (32.6) 31 (23.1) 0
aRestricted to patients with gastro-esophageal junction tumors; Siewert classification 1: adenocarcinoma of the distal 
esophagus, 2: true carcinoma of the cardia arising at the esophago-gastric junction, 3: subcardial gastric cancer infiltrating 
distal esophagus. ER = estrogen receptor, α = alpha, β = beta, AR = androgen receptor, GEJ = gastro-esophageal junction, 
PET = positron emission tomography, T = tumor, N = nodal.
Figure 2: Bar chart showing sex distribution (%) among esophageal adenocarcinoma patients who scored positively 
for ERα (n = 6), ERβ (n = 43) or AR (n = 4) expression. Abbreviations: ER = estrogen receptor, AR = androgen receptor, α = alpha, 
β = beta.
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Figure 3: (A–C) Tissue microarray staining in esophageal adenocarcinoma core samples according to ERα (A), ERβ (B) and AR 
expression. a: no staining [intensity 0]; b: weak staining [intensity 1]; c: moderate staining [intensity 2]; d: strong staining [intensity 3]. NB. 
No cores had ER-alpha and androgen receptor biomarkers scored at intensity 2/3. Abbreviations: ER = estrogen receptor, AR = androgen 
receptor, α = alpha, β = beta.
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(see Table 4). Similar to our study, earlier studies 
have identified positive ERβ expression [24–26, 28] 
and none or limited ERα expression [24, 25] in EAC. 
Additionally, in a small study of 33 patients, Liu et 
al. [26] reported that ERβ subtype isoforms (ERβ1, 
ERβ2, ERβ3 and ERβ5) were overexpressed in EAC 
compared to precursor lesions. Similar to our study, 
Al-Kyatt et al. [24] found limited ERα receptor 
expression (n = 1 case, defined as a H-score of 10), 
while moderate ERβ receptor expression was detected 
(n = 14 cases (40%), defined as a H-score of 30) 
[24]. Although the authors did not separate findings 
by histological subtype, the majority of the cohort 
(76%) had EAC. The authors also used quantitative 
reverse transcription polymerase chain reaction to 
evaluate ER tumor expression and reported that 
ERβ expression (ESR1, based on mRNA levels) 
was correlated with a shorter 1-year disease-
specific survival (p = 0.05), suggesting that ERβ 
may be a marker of poor biological behavior in EAC 
[24]. However, most likely due to small numbers 
(n = 28 EAC patients), a formal survival analysis was not 
conducted therefore limiting comparison with our study. 
In a small study of 31 EAC patients with available 
esophagectomy specimens, Akgun and colleagues [28] 
reported expression of ERβ in Barrett’s metaplasia 
negative for dysplasia, low-grade dysplasia, high-grade 
dysplasia and adenocarcinoma and observed a trend of 
increased expression as esophageal lesions progressed. 
Similarly, other studies have noted higher expression of 
ERβ in EAC compared to Barrett’s esophagus [26] and 
normal esophageal mucosa [25], and poorer differentiation 
Table 2: Overall survival, cancer-specific survival and recurrence-free survival according to sex hormone receptor 
expression
Overall survival Cancer-specific survival Recurrence-free survival
Biomarker Events Patients
Unadjusted 
HR 
(95% CI)
Adjusted 
HRa
(95% CI)
Events Patients Unadjusted HR 
(95% CI)
Adjusted 
HRa
(95% CI)
Events Patients Unadjusted HR 
(95% CI)
Adjusted 
HRa
(95% CI)
Estrogen receptor α
Negative 79 133 1.00 1.00 75 129 1.00 1.00 82 129 1.00 1.00
Positive 4 6 1.45 (0.53, 3.98)
1.32 
(0.41, 4.24) 3 5
1.21 
(0.38, 3.87)
1.14 
(0.29, 4.50) 4 6
1.29 
(0.17, 2.79)
1.36 
(0.44, 4.23)
Estrogen receptor β
Negative 56 95 1.00 1.00 52 91 1.00 1.00 56 91 1.00 1.00
Positive 28 43 1.14 (0.72, 1.80)
0.71 
(0.41, 1.21) 27 42
1.14 
(0.72, 1.82)
0.73 
(0.42, 1.28) 31 43
1.28 
(0.82, 2.00)
0.89 
(0.53, 1.48)
Androgen receptor
Negative 79 134 1.00 1.00 74 129 1.00 1.00 82 130 1.00 1.00
Positive 4 4 2.29 (0.83, 6.33)
1.50 
(0.49, 4.62) 4 4
2.42 
(0.88, 6.72)
1.48 
(0.48, 4.55) 4 4
1.98 
(0.72, 5.43)
1.50 
(0.49, 4.57)
Abbreviations: HR = Hazard ratio, CI = Confidence interval, α = alpha, β = beta.
aAdjusted for age at diagnosis, sex, nodal status, grade, PET response, circumferential resection margin status, lymphatic vascular invasion, primary site, smoking.
Table 3: Sex hormone receptor expression and EAC progression restricting to patients with gastro-esophageal junction 
tumors 
Overall survival Cancer-specific survival Recurrence-free survival
Biomarker Events Patients Unadjusted 
HR 
(95% CI)
Adjusted 
HRa
(95% CI)
Events Patients Unadjusted 
HR
(95% CI)
Adjusted 
HRa
(95% CI)
Events Patients Unadjusted 
HR 
(95% CI)
Adjusted 
HRa
(95% CI)
Estrogen receptor α
Negative 69 111 1.00 1.00 65 107 1.00 1.00 71 108 1.00 1.00
Positive 4 6 1.40 
(0.51, 3.87)
1.18 
(0.36, 3.90)
3 5 1.18 
(0.37, 3.78)
1.00 
(0.24, 4.08)
4 6 1.16 
(0.42, 3.18)
1.20 
(0.38, 3.77)
Estrogen receptor β
Negative 50 80 1.00 1.00 46 76 1.00 1.00 46 77 1.00 1.00
Positive 24 36 1.00 
(0.61, 1.64)
0.58 
(0.33, 1.03)
23 35 0.99 
(0.60, 1.64)
0.59 
(0.32, 1.07)
23 36 1.14 
(0.71, 1.84)
0.75 
(0.43, 1.29)
Androgen receptor
Negative 69 112 1.00 1.00 64 107 1.00 1.00 71 109 1.00 1.00
Positive 4 4 2.22 
(0.80, 6.18)
1.77 
(0.55, 5.67)
4 4 2.38 
(0.85, 6.63)
1.70 
(0.53, 5.47)
4 4 1.91 
(0.69, 5.26)
2.07 
(0.66, 6.51)
Abbreviations: HR = Hazard ratio, CI = Confidence interval, α = alpha, β = beta.
aAdjusted for age at diagnosis, sex, nodal status, grade, PET response, circumferential resection margin status, lymphatic vascular invasion, smoking.
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in EAC tumors that express ERβ [25, 28]. We did not find 
any significant differences in tumor grade according to 
sex hormone receptor expression. Some [30, 29] but not 
all previous studies [27] have reported weak-to moderate 
positive expression for AR in EAC with no differences in 
survival noted by expression status [30, 29] but sample 
sizes have been small (e.g. less than 20 EAC patients). In 
a small study of 11 EAC patients, Tihan et al. [30] noted 
that patients with AR-negative tumors included a larger 
proportion of longer-term survivors compared to patients 
with AR-positive tumors but no statistically significant 
difference in survival was apparent and no formal survival 
analysis was conducted. Variation in terms of sample sizes, 
selected patient groups, methods used to quantify receptor 
expression, as well as a lack of adjustment for important 
confounders in previous studies make direct comparisons 
with our study difficult. 
In our study, positive expression of ERβ was 
predominantly limited to males, which could be 
suggestive of a potential biological role for estrogen 
and/or ERβ receptor in EAC development. Within the 
minority of patients whose tumors expressed ERα and 
AR, the majority of expression was also detected in 
male EAC patients. Preclinical data have shown that 
estrogen and selective estrogen receptor modulator 
treatment decreases tumor growth, proliferation and 
increase apoptosis in EAC and Barrett’s esophagus 
cell lines [13, 14] and similar effects have been 
reported in vitro and in vivo for gastric [31, 32] 
and colorectal cancer [33] and esophageal squamous 
cell carcinoma (OSSC) [20, 34]. Interestingly, ERβ has 
been correlated with improved survival in non-small cell 
lung adenocarcinoma, particularly in men [35], although 
findings from other studies have been mixed [36, 37] and 
a recent pooled analyses found no association between 
ERβ expression and survival in NSCLC patients [38].
A possible mechanism of estrogen ‘protection’ might 
be mediated through estrogen receptors however, the role 
of activation of these receptors in re-epithelialisation 
following injury, and in the development of precursor 
states and EAC remains unclear. AR has been shown 
to be an important mediator of inflammatory signals in 
esophageal cancer progression [20] and overexpression 
of AR in vivo has been shown to promote cell migration, 
invasion and proliferation in esophageal cancer [13, 20]. 
Although risk estimates for EAC survival in our study 
Table 4: Previous studies of ERα, ERβ and AR expression and survival in esophageal adenocarcinoma cohorts
Study (year) Location Hormone receptor
Number of patients
Antibody 
(dilution)
Positive expression 
cut-off value 
(range)
Mortality HR (95% CI) pPositive 
expression
Negative 
expression
Al-Kyatt 
(2018)a UK ERα 1 33 Mouse (1:40) H-score ≥ 10 CS NR 0.05
b
ERβ 14 20 CS NR 0.02b
Kalayarasan 
(2008)c India ERα 0 15
Mouse 
(Prediluted) Quick score ≥ 1 (0–7)
d NR NR NR
ERβ 15 0 Mouse (1:50)
Liu (2004) USA ERβ-1 23 4 NR ≥1%e NR NR NR
ERβ-2 22 5
ERβ-3 27 0
ERβ-5 27 0
Akgun (2002) USA ERβ 23 0 Rabbit (1:500) ≥1% staining in cells NR NR NR
Awan (2007) UK AR 13 5 Mouse (1:50) Any focal/diffuse stainingf AC NR NS
Tiffin (2003) UK ER 8 12 NR Any mild, moderate or heavy stainingg NR NR NR
AR 1 19
Tihan (2001) USA AR 5 6 Mouse (1:200) Any focal/diffuse stainingh AC NR NS
Abbreviations: ER = estrogen receptor, AR = androgen receptor, NR = Not reported; NS = Non-significant; AC = All-cause; CS = Cancer-specific, α = alpha; 
β = beta
aIncludes esophageal adenocarcinoma (n = 28) and esophageal squamous cell carcinoma (6) patients.
bSurvival correlated with ERα (ESR1) and ERβ (ESR2) expression quantified using quantitative reverse transcription polymerase chain reaction.
cEndoscopic biopsy specimens used to determine sex hormone receptor expression.
dReceptor expression reported as ‘0 = no staining’; ‘1 = weak intensity (only visible at high magnification)’; ‘2 = moderate intensity (readily visible at low 
magnification)’; ‘3 = strong (strikingly positive even at low power. magnification)’; added to score for % of cells stained (0 = 0%; 1 = 1–25%; 2 = 26–50%; 
3 = 51–75%; 4 = 76–100%). Mean quick score was 6.6 for ERβ.
eReceptor expression reported as % of cells stained (0 = 0%; 1 = 1% to 10%; 2 = 11% to 25%; 3 = 26% to 50%; 4 = 51% to 75%; 5 ≥75%).
fReceptor expression reported as ‘no staining’; ‘focal positivity’ or ‘diffuse positivity’.
gReceptor expression reported as ‘absent’; ‘mild staining’; ‘moderate staining’ or ‘heavy staining’.
hReceptor expression reported as ‘no staining’; ‘focal positivity’ or ‘diffuse positivity’.
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suggested potential inverse associations for ERβ and 
positive associations for AR expression, our results were 
not statistically significant. Expression of sex hormone 
receptors, in particular ERβ, in EAC and their relationship 
with EAC development and progression therefore merits 
further investigation in larger population-based cohorts. 
Moreover, studies should include sufficient numbers 
of females to enable more meaningful sex-specific 
comparisons.
In our study, sensitivity analysis suggested that ERβ 
expression was associated with more marked reductions 
in all-cause and cancer-specific mortality in patients 
diagnosed with GEJ cancer. Although not as marked as 
EAC, gastric cardia adenocarcinomas, located close to the 
GEJ, show a similar sex disparity in incidence compared 
to EAC [10, 11] and proximal gastric cancers share 
similar aetiology and patterns of incidence with EAC 
[39]. Increased ERβ expression has been demonstrated in 
gastric cancer tissue compared to normal tissue [40, 41] 
and its presence has been associated with poorer prognosis 
[42, 43] however, other studies have shown no such 
association [40, 44]. No study has specifically investigated 
ERβ expression in cancer tissues of the proximal stomach. 
Epidemiological studies of markers of endogenous and 
exogenous estrogen exposures have suggested protective 
associations for gastric cancer [45], which are possibly 
more marked for gastric cardia adenocarcinomas [46], 
and preclinical evidence shows an increase in apoptosis 
and an inhibition of cell migration with estrogen 
administration in gastric cancer cell lines [32, 47]. A more 
marked prognostic benefit for ER receptor expression in 
GEJ tumors is therefore plausible but findings require 
replication in other large EAC cohorts. We did not 
have information on sex hormone receptor isoforms, 
which limited our ability to identify overexpression 
events directly linked to clinical EAC outcomes. Future 
studies should aim to investigate the complex interplay 
between wild-type and variant forms of sex hormone 
receptor expression in EAC and their relationship with 
prognosis. Moreover, considering the potential for inter- 
and intra-nuclear receptor crosstalk within ER, studies 
that examine alternative gene splicing via transcriptomic 
analysis of EAC tumour specimens both before and after 
chemotherapy may be warranted. Despite being the largest 
study conducted to examine the association between ERβ 
expression and EAC progression, caution is required in the 
interpretation of these results for GEJ patients as analysis 
was secondary in nature and based on reduced number of 
patients. 
Our study had a number of strengths and 
limitations. This is the first population-representative 
study to investigate sex hormone receptor expression 
in EAC tissue and their association with prognostic 
outcomes. Although we restricted our cohort to patients 
who underwent neoadjuvant chemotherapy prior to 
surgical resection, neoadjuvant therapy is now an integral 
component of EAC management [48] and we included 
all patients who underwent these treatments in Northern 
Ireland during the study period. Although progesterone 
receptor expression has been shown to be absent in both 
normal epithelial mucosa and oesophageal tumours [24], 
we did not investigate its expression, or expression of 
membrane bound G-protein coupled receptors (e.g. G 
protein-coupled estrogen receptor 1; GPER or GPR30). 
Future studies should explore the role of these additional 
receptors in OAC progression. Our study benefitted from 
a long follow-up period of (up to 9 years) and we had 
detailed clinico-pathological information, which allowed 
adjustment for confounders. Two observers (including 
a trained pathologist) independently scored all tumor 
cores and were blinded to clinical data. We utilised EAC 
tissue treated with chemotherapy, however it is unclear 
how treatment influences expression of sex hormone 
receptors. We used triplicate tumor cores to generate 
H-scores, thus limiting the potential for sampling bias. 
Insufficient tissue in diagnostic biopsies prohibited 
investigation of sex hormone receptor expression in EAC 
tissue prior to chemotherapy administration; however, pre-
treatment endoscopic biopsies may be subject to sampling 
error. Finally, although our study is the largest to date 
to examine sex hormone receptor expression and EAC 
outcomes, expression of ERα and AR was observed in 
only a minority of patients and small case numbers limited 
sensitivity and sub-group analyses (e.g. by sex). 
MATERIALS AND METHODS
Study cohort
We included all EAC patients who underwent neo-
adjuvant chemotherapy prior to surgical resection in 
Northern Ireland between 2004 and 2012. All patients 
received cisplatin-based neo-adjuvant chemotherapy 
at the Northern Ireland Cancer Centre followed by 
surgical resection at one of four regional surgical centres. 
EAC resection specimens were accessed through the 
Northern Ireland Biobank (NIB) (study number NIB15-
0176) which has ethical approval for the collection and 
storage of tumor tissue to support translational research 
[49]. To be included, patients had to have non-metastatic 
disease, have at least one available TMA tissue core with 
sufficient tumor for immunohistochemical scoring and 
have available clinico-pathological data. This study is 
in accordance with the Reporting Recommendations for 
Tumor Marker Prognostic Studies (REMARK) guidelines 
[50].
Clinico-pathological variables and follow-up
Clinical data were retrieved from a medical note 
review within the Northern Ireland Cancer Centre and 
pathology reports were reviewed for information on TNM 
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stage, tumor grade, primary tumor site, positron emission 
tomography (PET) response, lymphovascular invasion 
and circumferential margin involvement. EAC tumors 
were classified according to location using the Siewert 
classification [51]. Pathological staging was defined 
according to International Union Against Cancer (UICC) 
TNM staging, 7th edition. Information on study outcomes 
were retrieved from the Northern Ireland Cancer Centre and 
included overall survival (time to death from any cause), 
cancer-specific survival (time to death from EAC) and 
recurrence-free survival (time to clinical or pathological 
recurrence or death). Patients were followed from the date 
of EAC diagnosis until recurrence, death or end of study 
follow-up (31st December 2014).
Tumor molecular analysis
Tissue microarray construction and 
immunohistochemistry
Tissue microarrays (TMAs) were created within 
the Northern Ireland Molecular Pathology Laboratory 
(NI-MPL) at Queen’s University Belfast. A detailed 
description of TMA construction methods within the 
Northern Ireland Biobank are described elsewhere [52]. 
Immunohistochemical analysis was also conducted 
within the NI-MPL, where all markers were validated to 
investigate their association with other tumor sites (e.g. 
breast, prostate). A 3-µm thick section was deparafinized 
and endogenous peroxidase activity quenched with 0.3% 
hydrogen peroxide prior to slide labelling and staining using 
the Ventana Discovery XT® automated immunostainer 
(Ventana Medical Systems Inc, Tuscon, AZ) or the Bond 
Automated IHC/ISH Stainer (Leica Biosystems, Milton 
Keynes, UK). Slides were stained with rabbit (ERα) or 
mouse (AR, ERβ) monoclonal antibodies specific to the 
relevant sex hormone receptor. Antibody commercial 
suppliers included Ventana (cat no. 790-4324) for ERα, 
Dako (cat no. M7292) for ERβ and Abcam (cat no. ab9474) 
for AR. Cell signalling-clone numbers (and dilutions) were 
as follows; ERα: SP1 (RTU dilution), ERβ: PPG5/10 
(dilution 1 in 100) and AR: AR441 (1 in 200 dilution).
Biomarker scoring and assessment
Individual biomarker expression was assessed by 
two independent observers (JT & ÚMcM) using an online 
image viewer PathXL, following training and guidance 
from an expert gastrointestinal pathologist (DMcM). 
Both observers were blinded to clinical data. Nuclear, 
cytoplasmic or cell membrane staining was considered 
and we quantified sex hormone receptor expression by 
calculating H-scores that incorporated staining intensity 
and frequency, with consensus agreement of discordant 
results. Scoring was based on intensity (0 = no staining, 
1 = weak, 2 = moderate and 3 = strong staining observed) 
and percentage of tumor cells staining positive. These two 
values were multiplied to give a H-score between 1 and 
300 and the maximum H-score from the three cores was 
used for analysis. A dichotomous classification was used 
to categorise maximum H-scores into positive (any) or 
negative expression.
Statistical analysis
Differences between clinico-pathological 
characteristics according to ERα, ERβ and AR expression 
were calculated using chi-squared tests. Associations 
between sex hormone receptor expression (positive versus 
negative) and recurrence-free, cancer-specific and overall 
survival were investigated using Cox proportional hazards 
regression producing unadjusted and adjusted hazard ratios 
(HR) and 95% confidence intervals (CIs). All analyses 
were adjusted for age at diagnosis, sex, pathological nodal 
stage, grade, primary site (lower third or gastro-esophageal 
junction (GEJ)), lymphovascular invasion, circumferential 
margin involvement, PET response and smoking. An 
unknown category was included for missing values for 
smoking and PET response. Sensitivity analysis was 
conducted restricting the cohort to patients diagnosed with 
cancers of the GEJ. Due to the small number of females 
included, we were unable to conduct sub-group analysis 
by sex. All statistical analysis was performed using STATA 
14 (StataCorp LP, College Station, TX, USA). 
CONCLUSIONS
In a population-based cohort of EAC patients 
who underwent neo-adjuvant chemotherapy prior to 
surgical resection, we found little evidence of ERα or AR 
expression in EAC. Expression of ERβ was identified 
in one third of tumors, and although no significant 
associations were observed for the whole cohort, there was 
suggestive evidence that ERβ expression was associated 
with improved survival in patients with GEJ cancer. 
Considering that surgery alone is not a curative option 
for all stages of EAC and further therapeutic modalities 
are urgently required, further investigation is warranted to 
determine if the ER system could be a potential prognostic 
biomarker in EAC.
Abbreviations
EAC: esophageal adenocarcinoma; ER: estrogen 
receptor; AR: androgen receptor; FFPE: formalin-fixed 
paraffin embedded; GEJ: gastro-esophageal junctional; 
yp: pathologic stage classification determined after 
preoperative therapy.
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